Published in final edited form as:

Cell Mol Life Sci. 2008 June ; 65(12): 1836–1841. doi:10.1007/s00018-008-8158-3.

Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's Disease

J. N. Crawley

Laboratory of Behavioral Neuroscience, National Institute of Mental Health, Porter Neuroscience Research Center Building 35, Room 1C-903, Mail Code 3730, Bethesda, Maryland 20892–3730 (USA), Fax: +1 301 480 4630, e-mail: crawleyj@intr.nimh.nih.gov

Abstract

The neuropeptide galanin and its receptors are localized in brain pathways mediating learning and memory. Central microinjection of galanin impairs performance of a variety of cognitive tasks in rats. Transgenic mice overexpressing galanin display deficits in some learning and memory tests. The inhibitory role of galanin in cognitive processes, taken together with the overexpression of galanin in Alzheimer's disease, suggests that galanin antagonists may offer a novel therapeutic approach to treat memory loss in Alzheimer's patients. (Part of a Multi-author Review)

Keywords

Alzheimer's; fear conditioning; learning and memory; Morris water maze; receptor knockout mice; social transmission of food preference; transgenic mice

Introduction

The discovery of galanin overexpression in the basal forebrain in Alzheimer's disease prompted investigations into the role of galanin in cognitive functions. Galanin fibers and terminals hyperinnervate the remaining cholinergic neurons of the nucleus basalis of Meynert in middle to advanced stages of Alzheimer's [1–5]. Further, galanin receptor densities in the nucleus basalis and amygdala nuclei differ from age-matched controls at specific stages of Alzheimer's disease progression [6–8]. These clinical findings prompted the hypothesis that galanin plays a role in the memory decline that is the primary behavioral symptom of Alzheimer's disease.

To test the role of galanin in memory, galanin was administered centrally to rats. Impairments in performance were detected on multiple learning and memory tasks. Acquisition of the conventional Morris water maze task, a starburst radial maze spatial task, passive avoidance, and trace cued fear conditioning were blocked by pharmacological doses of galanin, administered before training trials [9–14]. Working memory on T-maze delayed alternation and operant non-matching to position working memory tasks were impaired by galanin pretreatment [15–22]. Memory consolidation after Morris water maze training was prevented by galanin administration 30 min after the training trials [23]. Further, galanin decreased long-term potentiation in rat and guinea pig hippocampal slices through inhibition of cholinergic Schaffer collaterals, relevant to synaptic plasticity involved in learning [24,25].

The contribution of endogenous galanin was investigated in rats using galanin receptor antagonist treatments. Three galanin receptor subtypes have been identified to date [26–28]. Peptidergic sequences and non-peptidergic compounds with moderate selectivity for each of the three subtypes have been developed [27–29]. Administration of the peptidergic galanin

receptor ligand M40 alone did not alter performance in normal rats on delayed nonmatching to position, although M40 blocked the inhibitory actions of galanin in this operant working memory task [21]. M40 potentiated the beneficial actions of a cholinergic agonist in cholinergically lesioned rats on delayed non-matching to position [30]. The peptidergic galanin receptor ligand M35 facilitated spatial learning in the Morris water maze when given alone in one unreplicated study [31].

The contribution of endogenous galanin to cognitive processes was further investigated in mice with targeted mutations in the galanin gene. Two lines of transgenic mice overexpressing the galanin gene, one on a dopamine β -hydroxylase promoter (D β H), that confers specificity to adrenergic neurons [32,33], and one on a platelet-derived growth factor promoter (PDGF) with a more widespread distribution in the brain [34–37]. Both have been tested on cognitive tasks. Galanin-overexpressing mice with the trans-gene on the D β H promoter displayed deficits on the more difficult components of several learning and memory tasks, including failing the probe trial test on the Morris water maze, impaired learning of social transmission of food preference and reduced fear conditioned freezing on the more challenging trace fear conditioning task [14,32,38–40]. In contrast, the D β H galanin transgenic mice were not different from their wildtype littermates on number of days to reach criterion on acquisition of the Morris water maze and an operant appetitive task, and were normal on attentional mechanisms in the 5-choice serial reaction time task [32,41,42]. Galanin-overexpressing transgenic mice with the transgene on the PDGF promoter displayed acquisition curves and selective quadrant search in the probe trial that did not differ from wildtype controls [37]. However, when tested during old age, at 19 months, the PDGF galanin transgenic mice were slower to learn the location of the hidden platform training on the Morris water maze task, spent less time in the trained quadrant during the delayed probe trial and displayed more thigmotaxis, while swim speeds did not differ between genotypes [43]. Conversely, galanin null mutant mice deficient in the galanin gene and galanin peptide also displayed a small deficit on the Morris water maze at older ages, and on a spatial object recognition task, indicating that too little galanin may also have deleterious consequences on cognition, perhaps related to the effects of galanin at early developmental stages [41,44]. A critical question in therapeutic development is which receptor subtype to target. In the absence of highly selective galanin receptor subtype antagonists that are soluble in vehicles appropriate for behavioral studies, knockout mice with targeted mutations in galanin receptor genes offer an opportunity to evaluate the individual contributions of the GalR1, GalR2 and GalR3 receptor subtypes in cognitive functions. Galanin receptor knockout mice with conventional mutations in the GalR1 and GalR2 receptor subtypes have been tested on several learning and memory tasks. GalR1 null mutants were not significantly different than wildtype littermates on Morris water maze acquisition and probe trial performance, social transmission of food preference, standard delay fear conditioned freezing or trace fear conditioned freezing [40,45]. GalR2 null mutants were not significantly different than wildtype littermates on the Morris water maze, standard delay contextual fear conditioning, or trace contextual and cued fear conditioning [46,47].

The lack of significant effects on learning and memory of galanin antagonist treatment in rats, and galanin receptor mutation in mice, argues against a strong role for endogenous galanin under baseline physiological conditions in normal learning and memory processes. One explanation is the frequency coding hypothesis for neuropeptide release. Higher frequencies of neuronal firing are required to release peptide transmitters than to release small-molecule classical transmitters such as glutamate and acetylcholine [48–51]. Standard learning and memory tasks may not activate neuronal firing to levels sufficient to release endogenous galanin. Galanin may be released only under extreme physiological conditions, and therefore exert its inhibitory effects on cognitive tasks only during very demanding behavioral tasks [52,53]. In the human brain, galanin may be released and exert its inhibitory effects similarly only under unusual physiological conditions, such as during the progression of

neurodegeneration in Alzheimer's disease, when high levels of galanin overexpression appear [5,53,54]. The frequency coding interpretation is supported by findings from the nociceptive flexor reflex in galanin-overexpressing transgenic mice, which display a lower magnitude of central sensitization during repeated stimulation of c-fibers, although the wind-up effect did not differ from wildtype controls [55]. Further, while GalR1 null mutants did not differ from wildtype at baseline on most nociceptive measures of baseline mechanical and heat sensitivity, GalR1 null mutants showed longer durations of pain-like behaviors after partial lesion of the sciatic nerve [56]. These findings support an interpretation of inhibitory actions of galanin on spinally mediate pain, but only when the system is perturbed [57]. Further, the inhibitory actions of galanin on the release of other neurotransmitters, including acetylcholine and glutamate [20,49,51,58–60], is greater in the D β H galanin transgenic mice than wildtype controls, primarily under conditions of high stimulation [51,60]. Consequently, the D β H galanin-overexpressing transgenic mice were more resistant to seizures than wildtype controls, indicating inhibitory effects of endogenous galanin only when the hippocampus is highly activated [51,61].

Another likely explanation is that galanin modulates cognitive functions through more than one of its three receptor subtypes. All three galanin receptors are members of the G-protein-coupled family of receptors with conventional seven transmembrane spanning regions, and linked to an inhibitory G-protein and cyclic-AMP signal transduction cascade [26–28,62,63]. However, GalR1 and GalR3 inhibit adenylate cyclase through a G_i pathway, while GalR2 acts at G_o, G_q, and G_i [27,28,63]. In addition, the anatomical distributions of each subtype differ across brain regions [64,65]. Understanding the biological actions of each galanin receptor subtype, and the interplay between them, may be necessary to effectively manipulate GalR1, GalR2 and GalR3 neurotransmission toward improving cognitive function. Thirdly, galanin has effects on anxiety-related behaviors, depression-related behaviors and stress-related responses [29,42,47,66–70]. Stress and related behaviors may indirectly or directly influence cognitive performance.

Actions of galanin in animal models have raised the possibility of novel galaninergic therapeutics for Alzheimer's, depression, neuropathic pain, drug abuse and epilepsy [53,54, 57,65,69,71–73]. A large and growing literature provides evidence that galanin inhibits the release of other neurotransmitters and inhibits signal transduction mechanisms common to many neurotransmitters [20,28,49,52,54,58,73]. The inhibitory neuromodulatory actions of galanin in many neuroanatomical pathways [74] encourages the development of galaninergic drugs as an adjunct to existing neuropharmacological treatments [28]. Combinations of a galaninergic compound with a cholinergic, glutamatergic, GABAergic, serotonergic or noradrenergic drug may enhance the clinical efficacy of available treatments and/or enable the use of combinations of lower doses of each drug to obtain the maximal therapeutic benefit.

Acknowledgments

Supported by the National Institute of Mental Health Intramural Research Program.

References

1. Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. *J. Comp. Neurol* 1988;273:543–557. [PubMed: 2463283]
2. Mufson EJ, Cochran E, Benzing W, Kordower JH. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. *Dementia* 1993;4:237–250. [PubMed: 7505157]

3. Bowser R, Kordower JH, Mufson EJ. A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. *Brain Pathol* 1997;2:723–730. [PubMed: 9161723]
4. Mufson EJ, Counts SE, Perez SE, Binder L. Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice. *Neuropeptides* 2005;39:233–237. [PubMed: 15893372]
5. Counts SE, Chen EY, Che S, Ikonomic MD, Wu J, Ginsberg SD, Dekosky ST, Mufson EJ. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. *Dement. Geriatr. Cogn. Disord* 2006;21:205–214. [PubMed: 16410678]
6. Mufson EJ, Decher DC, Basile M, Izenwasse S, Mash DC. Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis. *Neuropharmacology* 2000;39:1404–1412. [PubMed: 10818256]
7. Perez S, Basile M, Mash DC, Mufson EJ. Galanin receptor over-expression within the amygdala in early Alzheimer's disease: an in vitro autoradiographic analysis. *J. Chem. Neuroanat* 2002;24:109–116. [PubMed: 12191727]
8. McMillan PJ, Peskind E, Raskind MA, Leverenz JB. Increased galanin receptor occupancy in Alzheimer's disease. *Neurobiol. Aging* 2004;25:1309–1314. [PubMed: 15465628]
9. Sundström E, Archer T, Melander T, Hökfelt T. Galanin impairs acquisition but not retrieval of spatial memory in rats studied in the Morris swim maze. *Neurosci. Lett* 1988;88:331–335. [PubMed: 2455255]
10. Malin DH, Novy BJ, Lett-Brown A, Plotner RE, May BT, Radulescu SJ, Crothers MK, Osgood LD, Lake JR. Galanin attenuates one-trial reward learning. *Life Sci* 1992;50:939–944. [PubMed: 1372382]
11. Ukai M, Miura M, Kameyama T. Effects of galanin on passive avoidance response, elevated plus-maze learning, and spontaneous alternation performance in mice. *Peptides* 1995;16:1283–1286. [PubMed: 8545252]
12. Gleason TC, Dreiling JL, Crawley JN. Rat strain differences in response to galanin on the Morris water task. *Neuropeptides* 1999;33:265–270. [PubMed: 10657502]
13. Schött PA, Hökfelt T, Ögren SO. Galanin and spatial learning in the rat. Evidence for a differential role for galanin in subregions of the hippocampal formation. *Neuropharmacology* 2000;39:1386–1403. [PubMed: 10818255]
14. Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP, Long KC, Crawley JN. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. *Learn. Mem* 2002;9:178–190. [PubMed: 12177231]
15. Mastropaolo J, Nadi NS, Ostrowski NL, Crawley JN. Galanin antagonizes acetylcholine on a memory task in basal forebrain-lesioned rats. *Proc. Natl. Acad. Sci. USA* 1988;85:9841–9845. [PubMed: 2462255]
16. Givens BS, Olton DS, Crawley JN. Galanin in the medial septal area impairs working memory. *Brain Res* 1992;582:71–77. [PubMed: 1379875]
17. Robinson JK, Crawley JN. Intraventricular galanin impairs delayed non-matching to sample performance in rats. *Behav. Neurosci* 1993;107:458–467. [PubMed: 7687133]
18. Robinson JK, Crawley JN. Intraseptal galanin potentiates scopolamine impairment of delayed non-matching to sample. *J. Neurosci* 1993;13:5119–5125. [PubMed: 7504722]
19. Robinson JK, Crawley JN. Analysis of anatomical sites at which galanin impairs delayed nonmatching to sample in rats. *Behav. Neurosci* 1994;108:941–950. [PubMed: 7530011]
20. Robinson JK, Zocchi A, Pert A, Crawley JN. Galanin microinjected into the medial septum inhibits scopolamine-induced acetylcholine overflow in the rat ventral hippocampus. *Brain Res* 1996;709:81–87. [PubMed: 8869559]
21. McDonald MP, Crawley JN. Galanin receptor antagonist M40 blocks galanin-induced choice accuracy deficits on a delayed nonmatching to position task. *Behav. Neurosci* 1996;110:1025–1032. [PubMed: 8919005]
22. Schött PA, Bjelke B, Ögren SO. Distribution and kinetics of galanin infused into the ventral hippocampus of the rat: relationship to spatial learning. *Neuroscience* 1998;83:123–136. [PubMed: 9466403]

23. Kinney JW, Starosta G, Crawley JN. Central galanin administration blocks consolidation of spatial learning. *Neurobiol. Learn. Mem* 2003;80:42–54. [PubMed: 12737933]
24. Dutar P, Lamour Y, Nicoll RA. Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus. *Eur. J. Pharmacol* 1989;164:335–360. [PubMed: 2759181]
25. Sakuri E, Maeda T, Kaneko S, Akaike A, Satoh M. Galanin inhibits potentiation at Schaffer collateral-CA1 synapses in guinea-pig hippocampal slices. *Neurosci. Lett* 1996;212:21–24. [PubMed: 8823753]
26. Iismaa TP, Shine J. Galanin and galanin receptors. *Results Probl. Cell. Differ* 1999;26:257–291. [PubMed: 10453468]
27. Lu X, Lundström L, Langel Ü, Bartfai T. Galanin receptor ligands. *Neuropeptides* 2005;39:143–146. [PubMed: 15944002]
28. Lu X, Sharkey L, Bartfai T. The brain galanin receptors: targets for novel antidepressant drugs. *CNS Neurol. Disord. Drug Targets* 2007;6:183–192. [PubMed: 17511615]
29. Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hökfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. *Proc. Natl. Acad. Sci. USA* 2005;102:17489–17494. [PubMed: 16287967]
30. McDonald MP, Baker L, Wenk GL, Crawley JN. Co-administration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching-to-position choice accuracy in rats with cholinergic lesions. *J. Neurosci* 1998;18:5078–5085. [PubMed: 9634573]
31. Ögren SO, Hökfelt T, Kask K, Langel Ü, Bartfai T. Evidence for a role of the neuropeptide galanin in spatial learning. *Neuroscience* 1992;51:1–5. [PubMed: 1281521]
32. Steiner RA, Hohmann JG, Holmes A, Wrenn CC, Cadd G, Jureus A, Clifton DK, Luo M, Gutshall M, Ma SY, et al. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* 2001;98:4184–4189. [PubMed: 11259657]
33. He B, Counts SE, Perez SE, Hohmann JG, Steiner RA, Crawley JN, Mufson EJ. Ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice. *Neuroscience* 2005;33:371–380. [PubMed: 15885921]
34. Diez M, Koistinaho J, Kahn K, Games D, Hökfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein-initial observations. *Neuroscience* 2000;100:259–286. [PubMed: 11008166]
35. Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, Hökfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). *Neurobiol. Dis* 2003;14:579–594. [PubMed: 14678773]
36. Kokaia M, Holmberg K, Nanobashvili A, Xu ZQ, Kokaia Z, Lendahl U, Hilke S, Theodorsson E, Kahl U, Bartfai T, Lindvall O, et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. *Proc. Natl. Acad. Sci. USA* 2001;98:14006–14011. [PubMed: 11698649]
37. Kuteeva E, Hökfelt T, Ögren SO. Behavioural characterisation of transgenic mice overexpressing galanin under the PDGF-B promoter. *Neuropeptides* 2005;39:299–304. [PubMed: 15944026]
38. Crawley JN, Mufson EJ, Hohmann JG, Teklemichael D, Steiner RA, Holmberg K, Xu XJ, Wiesenfeld, Hallin Z, Bartfai T, Hökfelt T. Galanin overexpressing transgenic mice. *Neuropeptides* 2002;36:145–156. [PubMed: 12359505]
39. Wrenn CC, Harris AP, Saavedra MC, Crawley JN. Social transmission of food preference in mice: methodology and application to galanin-overexpressing transgenic mice. *Behav. Neurosci* 2003;117:21–31. [PubMed: 12619904]
40. Rustay NR, Wrenn CC, Kinney JW, Holmes A, Bailey KR, Sullivan TL, Harris AP, Long KC, Saavedra MC, Starosta G, et al. Galanin impairs performance on learning and memory tasks: findings from galanin transgenic and GAL-R1 knockout mice. *Neuropeptides* 2005;39:239–243. [PubMed: 15944016]
41. Massey PV, warburton EC, Wynick D, Brown MW, Bashir ZI. Galanin regulates spatial memory but not visual recognition memory or synaptic plasticity in perirhinal cortex. *Neuropharmacology* 2003;44:40–48. [PubMed: 12559120]

42. Wrenn CC, Holmes A. The role of galanin in modulating stress-related neural pathways. *Drug News Perspect* 2006;19:461–467. [PubMed: 17160146]
43. Pirondi S, D'Intino G, Gusciglio M, Massella A, Giardino L, Kuteeva E, Ögren SO, Hökfelt T, Calza L. Changes in brain cholinergic markers and spatial learning in old galanin-overexpressing mice. *Brain Res* 2007;1138:10–20. [PubMed: 17266943]
44. O'Meara G, Coumis U, Ma SY, Kehr J, Mahoney S, Bacon A, Allen SJ, Holmes F, Kahl U, Wang FH, et al. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. *Proc. Natl. Acad. Sci. USA* 2000;97:11569–11574. [PubMed: 11016971]
45. Wrenn CC, Kinney JW, Marriott LK, Holmes A, Harris AP, Saavedra MC, Starosta G, Innerfield CE, Jacoby AS, Shine J, et al. Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. *Eur. J. Neurosci* 2004;19:1384–1396. [PubMed: 15016096]
46. Gottsch ML, Zeng H, Hohmann JG, Weinshenker D, Clifton DK, Steiner RA. Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). *Mol. Cell. Biol* 2005;25:4804–4811. [PubMed: 15899880]
47. Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. *Pharmacol. Biochem. Behav* 2007;86:8–20. [PubMed: 17257664]
48. Hökfelt T, Millhorn D, Seroogy K, Tsuruo Y, Ceccatelli S, Lindh B, Meister B, Melander T, Schalling M, Bartfai T, et al. Coexistence of peptides with classical neurotransmitters. *Experientia* 1987;43:768–780. [PubMed: 2885215]
49. Consolo S, Bertorelli R, Girotto P, La Porta C, Bartfai T, Parenti M, Zambelli M. Pertussis toxin sensitive G-protein mediates galanin's inhibition of scopolamine-evoked acetylcholine release in vivo and carbachol-stimulated phosphoinositide turnover in rat ventral hippocampus. *Neurosci. Lett* 1991;126:29–32. [PubMed: 1714064]
50. Consolo S, Baldi G, Russi G, Civenni G, Bartfai T, Vezzani A. Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. *Proc. Natl. Acad. Sci. USA* 1994;91:8047–8051. [PubMed: 7520174]
51. Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, Steiner RA, Wynick D, Wasterlain CG. Modulation of hippocampal excitability and seizures by galanin. *J. Neurosci* 2000;20:6276–6276. [PubMed: 10934278]
52. Wrenn CC, Crawley JN. Pharmacological evidence supporting a role for galanin in cognition and affect. *Prog. Neuropsychopharm. Biol. Psychiatr* 2001;25:283–299.
53. Crawley, JN. Galanin, role in memory processes and Alzheimer's disease. In: Adelman, G.; Smith, BH., editors. *Encyclopedia of Neuroscience*. New York: Elsevier; 2006.
54. Counts SW, Perez SE, Kahl U, Bartfai T, Bowser RP, Deecker DC, Mash DC, Crawley JN, Mufson EJ. Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. *CNS Drug Rev* 2001;7:445–470. [PubMed: 11830760]
55. Grass S, Jacoby AS, Iismaa TP, Crawley JN, Xu XJ, Wiesenfeld-Hallin Z. Flexor reflex excitability in mice lacking galanin receptor galanin-R1. *Neurosci. Lett* 2003;345:153–156. [PubMed: 12842279]
56. Blakeman KH, Hao JX, Xu XJ, Jacoby AS, Shine J, Crawley JN, Iismaa T, Wiesenfeld-Hallin Z. Hyperalgesia and increased neuropathic pain-like response in mice lacking galanin receptor 1 receptors. *Neuroscience* 2003;117:221–227. [PubMed: 12605908]
57. Wiesenfeld-Hallin Z, Xu XJ, Crawley JN, Hökfelt T. Galanin and spinal nociceptive mechanisms: recent results from transgenic and knock-out models. *Neuropeptides* 2005;39:207–210. [PubMed: 15944013]
58. Fisone G, Wu CF, Consolo S, Nordström O, Brynne N, Bartfai T, Melander T. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. *Proc. Natl. Acad. Sci. USA* 1987;84:7339–7343. [PubMed: 2444980]
59. Zini S, Roisin MP, Langel Ü, Barfai T, Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. *Eur. J. Pharmacol* 1993;245:1–7. [PubMed: 7682961]
60. LaPlante F, Crawley JN, Quirion R. Selective reduction in ventral hippocampal acetylcholine release in awake galanin-treated rats and galanin-overexpressing transgenic mice. *Regul. Pept* 2004;122:91–98. [PubMed: 15380926]

61. Mazarati AM. Galanin and galanin receptors in epilepsy. *Neuropeptides* 2004;38:331–343. [PubMed: 15567469]
62. Branchek T, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. *Trends Pharmacol. Sci* 2000;21:109–117. [PubMed: 10689365]
63. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. *Pharmacol Ther* 2007;115:177–207. [PubMed: 17604107]
64. Lundström L, Elmquist A, Bartfai T, Langel Ü. Galanin and its receptors in neurological disorders. *Neuromolecular Med* 2006;7:157–180.
65. Walton KM, Chin JE, Duplantier AJ, Mather RJ. Galanin function in the central nervous system. *Curr. Opin. Drug. Discov. Dev* 2006;9:560–570.
66. Holmes A, Yang RJ, Crawley JN. Evaluation of an anxiety-like phenotype in galanin overexpressing transgenic mice. *J. Mol. Neurosci* 2002;18:151–165. [PubMed: 11931346]
67. Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L, Vishwanath J, Saavedra MC, Innerfield CE, Jacoby AS, Shine J, et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. *Neuropsychopharmacology* 2003;28:1031–1044. [PubMed: 12700679]
68. Barrera G, Echevarria DJ, Poulin JF, Laforest S, Drolet G, Morilak DA. One for all or one for one: does co-transmission unify the concept of a brain galanin ‘system’ or clarify any consistent role in anxiety? *Neuropeptides* 2005;39:289–292. [PubMed: 15944024]
69. Barr AM, Kinney JW, Hill MN, Lu X, Biros S, Rebek J, Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. *Neurosci. Lett* 2006;11:111–115. [PubMed: 16854525]
70. Wrenn CC, Turchi JN, Schlosser S, Dreiling JL, Stephenson DA, Crawley JN. Performance of galanin transgenic mice in the 5-choice serial reaction time attentional task. *Pharmacol. Biochem. Behav* 2006;83:428–440. [PubMed: 16626795]
71. Mazarati A, Langel Ü, Bartfai T. Galanin: an endogenous anticonvulsant? *Neuroscientist* 2001;7:506–517. [PubMed: 11765128]
72. Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua XY, Yaksh T, Haberhauer G, Ceide SC, Trembleau L, et al. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. *Proc. Natl. Acad. Sci. USA* 2004;101:10470–10475. [PubMed: 15240875]
73. Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? *CNS Neurol. Disord. Drug Targets* 2006;5:225–232. [PubMed: 16611095]
74. Hökfelt, T. Neuropeptides; Galanin and its receptors: introduction to the Third International Symposium; 21–22 October 2004; San Diego, California, USA. 2005. p. 125-142.
75. Aspley S, Fone KC. Galanin fails to alter both acquisition of a two trial per day water maze task and neurochemical markers of cholinergic or serotonergic neurones in adult rats. *Brain Res* 1993;622:330–336. [PubMed: 7694768]
76. Stefani MR, Gold PE. Intra-septal injections of glucose and glibenclamide attenuate galanin-induced spontaneous alternation performance deficits in the rat. *Brain Res* 1998;813:50–56. [PubMed: 9824666]
77. Shandra AA, Mazarati AM, Servetskii KL. Influence of the neuropeptide galanin on active avoidance in rats. *Neurosci. Behav. Physiol* 1994;24:429–432. [PubMed: 7530815]
78. McDonald MP, Wenk GL, Crawley JN. Analysis of galanin and the galanin antagonist, M40, on delayed non-matching to position performance in rats lesioned with the cholinergic immunotoxin ¹⁹²IgG-saporin. *Behav. Neurosci* 1997;111:552–563. [PubMed: 9189270]

Table 1

Pharmacological and endogenous actions of galanin in rodent learning and memory tasks.

A) Central administration of galanin to rats		
Task	Effect on cognition	Reference
Morris water task	Slower acquisition curve	[9]
	No effect	[75]
	Slower acquisition with no change in retention	[22]
	Deficit in acquisition (strain-dependent)	[12]
	Deficit in consolidation	[23]
Starburst radial maze	Deficit in acquisition	[10]
T-maze delayed alternation	Reduction in choice accuracy	[16]
	Inhibition of acetylcholine induced improvement after cholinergic lesion	[15]
Spontaneous alternation	Decrease in choice accuracy	[76]
Passive avoidance	Decrease in step-down latency	[11]
Active avoidance	Decrease in avoidance responses during retention and extinction trials	[77]
Delayed nonmatching to position	Decrease in choice accuracy	[17,19]
	Potential of scopolamine-induced reduction in choice accuracy	[18]
	Decrease in choice accuracy blocked by M40	[21]
	Potential of decrease in choice accuracy after cholinergic lesion	[78]
	Potential of M1 agonist improvement after cholinergic lesion	[30]
B) Targeted gene Mutations in galanin and its receptors		
Mutation	Effect on cognition	Reference
Galanin-overexpressing transgenic mice		
GAL-tg (D β H promoter)	Impaired on Morris water maze probe trial	[32]
GAL-tg (D β H promoter)	Impaired on trace fear conditioning	[14]
GAL-tg (D β H promoter)	Impaired on social transmission of food preference	[39]
GAL-tg (PDPF promoter)	Normal at young age on Morris water maze acquisition	[37]
GAL-tg (PDPF promoter)	Impaired at old age on Morris water maze acquisition	[43]
Galanin peptide knockout mice		
GAL null mutant	Impaired at older age on Morris water maze acquisition	[44]
GAL null mutant	Impaired on spatial object recognition	[41]
Galanin receptor knockout mice		

A) Central administration of galanin to rats

Task	Effect on cognition	Reference
GAL-R1 null mutant	Normal on Morris water maze	[45]
GAL-R1 null mutant	Normal on social transmission of food preference	[45]
GAL-R1 null mutant	Impaired on trace cued fear conditioning	[45]
GAL-R2 null mutant	Normal on Morris water maze	[47]
GAL-R2 null mutant	Normal on trace contextual and cued fear conditioning	[47]